Exploración del panorama terapéutico emergente del mieloma múltiple: una revisión exploratoria
DOI:
https://doi.org/10.35434/rcmhnaaa.2026.192.2937Palabras clave:
Mieloma múltiple, Fármacos inmunomoduladores, Inhibidores del proteasoma, Terapia con células T receptoras de antígenos quiméricosResumen
Se desarrolló una revisión exploratoria en base a las normativas PRISMA-ScR, cuyo propósito fue, mapear la evidencia terapéutica disponible aplicada al mieloma múltiple (MM), comparando terapias emergentes como los inmunomoduladores (IMiD), inhibidores del proteasoma (IP), anticuerpos monoclonales y terapias CAR-T, en contraste con la terapéutica convencional. La revisión incluyo PubMed, Scopus y Web of Science (2023-2024), después de una filtración de estudios, se optó por la selección de 6 estudios observacionales (n=1.717 pacientes). Los resultados evidencian que la combinación de IMiD con IP mejoran la SG y SLP en contraste con monoterapias. Las terapias de antígeno de maduración de células B (BCMA) mejoran la SG del MM penta-refractario hasta 29 meses, en tanto el trasplante autólogo de células madre (ASCT) y daratumumab reafirman la SLP, de igual forma el mantenimiento con lenalidomida en pacientes con enfermedad residual mínima negativa (MRD-). Por el contrario, la quimioterapia tradicional mostró mayor toxicidad y eficacia mínima. Dichos hallazgos destacan el impacto positivo de la terapéutica combinada, dirigida y de mantenimiento en el pronóstico del MM.
Descargas
Referencias
1. Grillone K, Ascrizzi S, Cremaschi P, Amato J, Polerà N, Croci O, et al. An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma. Blood 2024;144(16):1705-21. doi: 10.1182/blood.2023021991
2. Scionti F, Juli G, Rocca R, Polerà N, Nadai M, Grillone K, et al. TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma. Journal of Experimental & Clinical Cancer Research [Internet] 2023 [citado 2025 ene 30];42(1):71. doi: 10.1186/s13046-023-02633-0
3. Boulos JC, Chatterjee M, Shan L, Efferth T. In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia. Cancers (Basel) 2023;15(16):4136. doi: 10.3390/cancers15164136
4. Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood [Internet] 2024; blood.2024025987. doi: 10.1182/blood.2024025987
5. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, et al. Retreatment of multiple myeloma with previously refractory drugs. Blood Advances [Internet] 2024 [citado 2025 ene 30];8(24):6321-8. doi: 10.1182/bloodadvances.2024014723
6. Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F, et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. JNCI: Journal of the National Cancer Institute [Internet] 2025 [citado 2025 may 16];117(5):907-14. doi: 10.1093/jnci/djae321
7. Sun K, Wu H, Zhu Q, Gu K, Wei H, Wang S, et al. Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: population-based estimates from GLOBOCAN 2022. eClinicalMedicine [Internet] 2025 [citado 2026 ene 27];83. doi: 10.1016/j.eclinm.2025.103193
8. Mina R, Radhakrishnan A, Vasudevan A, Sapra S, Bates A, Parker J, et al. Years of life lost to multiple myeloma remains high: A targeted literature review. Blood [Internet] 2025 [citado 2026 ene 27]; 146:2804. doi: 10.1182/blood-2025-2804
9. National Cancer Institute (NCI). SEER Cancer Stat Facts: Myeloma [Internet]. SEER2025 [citado 2026 ene 27]; Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
10. Javed H, Khan I, Maqbool SM, Rehman A, Raja H a. A, Rafique A, et al. WITHDRAWN: 1314eP Trends in myeloma incidence, mortality, and survival rates in the United States (1975-2022): A comparative analysis of recent and long-term data from the surveillance, epidemiology, and end results (SEER) program. Annals of Oncology [Internet] 2025 [citado 2026 ene 28]; 36:S1654. doi: 10.1016/j.annonc.2025.08.1946
11. Instituto Nacional de Enfermedades Neoplásicas (INEN). Registro de Cáncer de Lima Metropolitana 2013–2015 [Internet]. Lima: 2018. Available from: https://portal.inen.sld.pe/wp-content/uploads/2022/01/REGISTRO-DE-CANCER-DE-LIMA-METROPOLITANA-2013-2015.pdf?utm_source
12. Peña C, Rojas-Vallejos J, Espinoza M, Donoso J, Soto P, Cardemil D, et al. Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos. Revista Médica de Chile [Internet] 2019 [citado 2025 may 18];147(12). doi: 10.4067/S0034-98872019001201561
13. García WR, Fagundo J carlos jaime, Urquiza yanisleidy V, Saez SS, Fernandez JD. Resultados del trasplante autólogo de progenitores hematopoyéticos en pacientes con mieloma múltiple. Revista Cubana de Hematología, Inmunología y Hemoterapia [Internet] 2022 [citado 2025 may 18];38(4). Available from: https://revhematologia.sld.cu/index.php/hih/article/view/1743
14. Kazandjian D, Mo CC, Landgren O, Richardson PG. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol 2020;191(5):692-703. doi: 10.1111/bjh.16764
15. Poczta A, Rogalska A, Marczak A. Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches. Journal of Clinical Medicine [Internet] 2021 [citado 2026 ene 28];10(9):1841. doi: 10.3390/jcm10091841
16. Gong L, Sun H, Liu L, Sun X, Fang T, Yu Z, et al. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. Haematologica [Internet] 2024;109(11):3650-69. doi: 10.3324/haematol.2024.285099
17. Lu Q, Li H, Wu Z, Zhu Z, Zhang Z, Yang D, et al. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. J Nanobiotechnology [Internet] 2024;22(1):279. doi: 10.1186/s12951-024-02512-6
18. Guo J, Zhang Z, Wang H, Li Q, Fan M, Zhang W, et al. SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection. Clin Exp Med [Internet] 2024;24(1):28. doi: 10.1007/s10238-023-01272-1
19. Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther [Internet] 2024;31(5):667-86. doi: 10.1038/s41417-024-00750-2
20. Wu L, Feng Y, Huang Y, Feng J, Hu Y, Huang H. CAR-T Cell Therapy: Advances in Kidney-Related Diseases. Kidney Dis (Basel) [Internet] 2024;10(2):143-52. doi: 10.1159/000536194
21. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth [Internet] 2020;18(10):2119-26. doi: 10.11124/JBIES-20-00167
22. Fan H, Wang W, Zhang Y, Wang J, Cheng T, Qiu L, et al. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biology & Medicine [Internet] 2023 [citado 2025 ene 30];20(1):77-87. doi: 10.20892/j.issn.2095-3941.2022.0612
23. Liang D, Li X, Bai S, Wang Q, Zeng M, Feng D, et al. Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study. Cancer Med 2024;13(20):e70270. doi: 10.1002/cam4.70270
24. Atrash S, Mammadzadeh A, Peng F, Alkharabsheh O, Afrough A, Cui W, et al. Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy. Cancers (Basel) 2023;15(11):2891. doi: 10.3390/cancers15112891
25. Hashmi H, Atrash S, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, et al. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. Transplantation and Cellular Therapy [Internet] 2023 [citado 2025 ene 30];29(4):262.e1-262.e6. doi: 10.1016/j.jtct.2023.01.013
26. Salgado AB dos S, Magalhães RJP, Pontes RM, Barbosa E da S, Flores-Montero J, Sanoja-Flores L, et al. Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil. Cancers [Internet] 2023 [citado 2025 ene 30];15(5):1605. doi: 10.3390/cancers15051605
27. Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, Dima D, et al. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev 2023;61:101100. doi: 10.1016/j.blre.2023.101100
28. Pelon M, Krzeminski P, Tracz-Gaszewska Z, Misiewicz-Krzeminska I. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells. Front Pharmacol [Internet] 2024 [citado 2025 may 18];15. doi: 10.3389/fphar.2024.1351565
29. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia [Internet] 2010 [citado 2025 oct 13];24(1):22-32. doi: 10.1038/leu.2009.236
30. Teoh PJ, Koh MY, Mitsiades C, Gooding S, Chng WJ. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica [Internet] 2024 [citado 2025 may 18];110(5):1074-91. doi: 10.3324/haematol.2024.285636
31. Radhakrishnan V, Golla U, Kudva AK. Role of Immune Cells and Immunotherapy in Multiple Myeloma. Life [Internet] 2024 [citado 2025 may 18];14(4):461. doi: 10.3390/life14040461
32. Krönke J, Hurst SN, Ebert BL. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology [Internet] 2014 [citado 2025 may 18];3(7):e941742. doi: 10.4161/21624011.2014.941742
33. Saltarella I, Altamura C, Campanale C, Laghetti P, Vacca A, Frassanito MA, et al. Anti-Angiogenic Activity of Drugs in Multiple Myeloma. Cancers [Internet] 2023 [citado 2025 may 18];15(7):1990. doi: 10.3390/cancers15071990
34. Zhong X, Ma H. Targeting CD38 for acute leukemia. Front Oncol [Internet] 2022 [citado 2025 may 18];12. doi: 10.3389/fonc.2022.1007783
35. van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood [Internet] 2018 [citado 2025 may 18];131(1):13-29. doi: 10.1182/blood-2017-06-740944
36. Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, et al. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. European Journal of Haematology [Internet] 2024 [citado 2025 may 18];113(5):593-605.doi: 10.1111/ejh.14270
37. Kassem S, Diallo BK, El-Murr N, Carrié N, Tang A, Fournier A, et al. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood [Internet] 2022 [citado 2025 may 18];139(8):1160-76. doi: 10.1182/blood.2021012448
38. Morè S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences. Cancers [Internet] 2023 [citado 2025 may 19];15(11):2948. doi: 10.3390/cancers15112948
39. Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, et al. BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv 2025;9(5):1171-80. doi: 10.1182/bloodadvances.2024014345
40. Rees M, Abdallah N, Yohannan B, Gonsalves WI. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol [Internet] 2024 [citado 2025 may 19];15. doi: 10.3389/fimmu.2024.1424925
41. Andersen KT, Hinge M, Szabo AG, Segel E, Ormstrup T, Holdgaard PC, et al. Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. Clin Hematol Int [Internet] 2020 [citado 2025 may 19];2(1):35-9. doi: 10.2991/chi.d.200116.001
42. Liang D, Bai S, Feng D, Chen G, Liang Y, Wang H. Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma. BMC Cancer [Internet] 2024 [citado 2025 may 19];24(1):1123. doi: doi.org/10.1186/s12885-024-12880-9
43. Portuguese AJ, Banerjee R, Chen G, Reddi S, Cowan AJ. Novel Treatment Options for Multiple Myeloma. JCO Oncol Pract [Internet] 2025 [citado 2025 jun 9];0(0):OP-24-00752. doi: 10.1200/OP-24-00752
44. Rodriguez C, Catamero D. Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma. J Adv Pract Oncol [Internet] 2023 [citado 2025 jun 9];14(3):252-6. doi: 10.6004/jadpro.2023.14.3.14
45. Bolick C, Thunuguntla P, Colbert D, Daly S, Rajana Y, King J, et al. RNA Modifications on Long Non-Coding RNAs in Multiple Myeloma. Blood [Internet] 2024 [citado 2025 jun 9];144:6836. doi: 10.1182/blood-2024-207137
Descargas
Publicado
Número
Sección
Categorías
Licencia
Derechos de autor 2026 Edwin Michel Vera-Mendoza
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
